Challenges in targeted drug development and treatment in lung cancer скачать в хорошем качестве

Challenges in targeted drug development and treatment in lung cancer

Bruce Johnson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the challenges in development of targeted agents for use in lung cancer. Efforts to comprehensively genotype lung cancers and identify efficacious targeted therapies are ongoing. There are currently 7 different genomic changes with approved agents for use in clinical practice. However, there are difficulties associated with drug development and deployment. Firstly, thorough biomarker testing of lung patients is required to identify those with genomic changes that are eligible for targeting, yet surveys show many patients are not being tested. Additionally, there are significant costs associated with the trials needed for drug approval. Since the treatments are only beneficial to a small subset of patients, balancing these costs with the expected revenue from a small target market is a challenge. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.